CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting Conditions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-03

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the oral bioavailability of 'CreNeuroS CNS Fish Oil Plus Softgels \[Eicosapentaenoic Acid (as Ethyl Ester) 342 mg; L-5-methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals\] (Test Product) compared with co-administration of Omega-3-acid Ethyl ester 1000 mg Capsules (Reference Product-1) and L-methylfolate Calcium 7.5 mg Capsules (Reference Product-2) in healthy human adult subjects under fasting conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides

NCT02625870

Hypertriglyceridemia

UNKNOWN PHASE3

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

NCT00746811

Primary Hypercholesterolemia

COMPLETED PHASE4

Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels

NCT00578578

Coronary Artery Disease Inflammatory Response Atherosclerosis

TERMINATED PHASE4

Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia

NCT01034540

Hypertriglyceridemia

COMPLETED NA

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

NCT02359045

Relative Bioavailability AUC Cmax +1 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an Open-Label, Balanced, Randomized, Single Dose, Two-Treatment, Two-Sequence, Two-Period ,Two-Way Crossover oral Bioavailability study of CreNeuroSTM CNS Fish Oil Plus Softgels \[Eicosapentaenoic Acid (as Ethyl Ester) 342 mg; L-5-methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals\] (Test Product) compared with co-administration of Omega-3-acid Ethyl ester 1000 mg Capsules (Reference Product-1) and L-methylfolate Calcium 7.5 mg Capsules (Reference Product-2) in healthy human adult subjects under fasting conditions.

A total number of 14 normal healthy adult human subjects will be included in the study.

A total of 35 blood samples will be collected from each subject in each study period.

There will be atleast 28 days washout period between two treatments in the study.

The following analytes will be determined in plasma using a validated LC-MS/MS (Liquid chromatography tandem mass spectrometry) method.

* Total Eicosapentaenoic Acid (EPA) in plasma
* L-5-methyltetrahydrofolate (L-5-MTHF) in plasma

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bioavailability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CreNeuroS CNS Fish Oil Plus Softgel

CreNeuroS CNS Fish Oil Plus Softgel \[380 mg of fish oil contains Eicosapentaenoic Acid (EPA) （as EE）342 mg; L-5- Methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals\] Distributed by: Fidelity Biopharma Co., USA.

Group Type EXPERIMENTAL

CreNeuroS CNS Fish Oil Plus Softgel [380 mg of fish oil contains Eicosapentaenoic Acid (EPA) （as EE）342 mg; L-5- Methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals]

Intervention Type DIETARY_SUPPLEMENT

Test product

Reference Product

Reference product (R1): Vascepa® (Icosapent ethyl) 1000 mg Capsules Manufactured by：Patheon Softgels B.V. Reference product (R2): Deplin® (L-methylfolate Calcium) 7.5 mg Capsules Manufactured by：Alfasigma USA, Inc.

Group Type ACTIVE_COMPARATOR

Vascepa® (Icosapent ethyl) 1000 mg Capsules, Deplin® (L-methylfolate Calcium) 7.5 mg Capsules

Intervention Type DIETARY_SUPPLEMENT

Reference product

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CreNeuroS CNS Fish Oil Plus Softgel [380 mg of fish oil contains Eicosapentaenoic Acid (EPA) （as EE）342 mg; L-5- Methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals]

Test product

Intervention Type DIETARY_SUPPLEMENT

Vascepa® (Icosapent ethyl) 1000 mg Capsules, Deplin® (L-methylfolate Calcium) 7.5 mg Capsules

Reference product

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Healthy human subjects aged between 18 and 45 years (including both).

* Subjects with a BMI between 18.50-25.00 Kg/m2 (including both) but body weight not less than 50 Kgs.
* Subjects with normal health as determined by personal medical history, Clinical examination and laboratory examinations including serological tests during the screening as per section 5.3.
* Subjects having normal 12-lead electrocardiogram (ECG).
* Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 180 days prior to the check-in of Period-I.
* Subjects able to communicate effectively.
* Subjects willing to give written informed consent and adhere to all the requirements of this protocol.
* Subject is a non-smoker or moderate smoker (not more than 10 cigarettes or beedis/day).
* Subject is a non-alcoholic or non-alcoholic abuse (Alcohol abuse will be defined as \>14 drinks per week (1 drink=360 mL beer, 150 mL wine or 45 mL hard liquor).

Exclusion Criteria

* • Subjects having contraindications or hypersensitivity to study drug or related group of drugs.

* An unusual or abnormal diet, for whatever reason within 48.00 hours prior to admission of each period, e.g., fasting due to religious reasons.
* History of Hypertension.
* History of dehydration from diarrhea, vomiting or any other reason within a period of 24.00 hours prior to study admission of each study period.
* Positive results for drugs of abuse (benzodiazepines, cocaine, opioids, amphetamines, cannabinoids and barbiturates) in urine during the admission of each study period.
* Positive results for alcohol consumption during the admission of each study period.
* Intolerance to venipuncture.
* History or presence of any medical condition or disease according to the opinion of the physician.
* History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
* Difficulty with donating blood.
* Major illness during 90 days before check-in.
* Participation in a drug Research study within past 90 days of check-in.
* Donation of blood (i.e. one unit or 350 mL) in the past 90 days before check-in.
* Difficulty in swallowing solid dosage forms like tablets or capsules.

Volunteers who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes